A study from Department of Medicine, University of Chicago, Chicago, Illinois, USA shows that “Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation.” This study was published in the February 2, 2014 issue of J Clin Invest by Prof. Eugene B. Chang & Dr. Xiaorong Zhu.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for Inflammatory Bowel disease (IBD): E2F3 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene. Thus, this study suggests that pharmacological formulations encompassing “E2F3 activators” may be used in the treatment of Inflammatory Bowel disease (IBD).
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $500*
Undisclosed information: How E2F3 decreases tissue injury in inflammatory bowel disease (IBD)
To cite: Boominathan, Molecular therapy for Inflammatory Bowel disease (IBD): E2F3 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene, 08/February/2015, 23.32, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
